The structural problem with the current wave of precision medicine AI coverage is that every claim of scale is cited to market research firms, not to clinical trial registries or regulatory dossiers. A projection placing the sector at over $120 billion by 2040 at a 28% compound annual growth rate tells investors what the addressable market could look like — it says nothing about which patients will benefit or when. That is not a minor omission; it is the entire question. The companies buying into these forecasts — Microsoft, PathAI,…